Essilorluxottica (OTC) ((ESLOY)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Essilorluxottica has announced a new clinical study titled ‘Etude De L’Effet De Filtres Sur L’Eblouissement D’Inconfort,’ aimed at evaluating the effectiveness of filters in reducing discomfort glare in healthy adults. The study seeks to measure the glare protection offered by two different filters compared to no filter, using the Lumiz 100™ device. This research is significant as it could lead to advancements in eyewear technology, enhancing visual comfort for users.
The intervention being tested involves a filter comparison, where participants will use the Lumiz 100™ device to assess their discomfort thresholds under three conditions: no filter and two experimental filters. This approach is designed to quantify the level of glare protection each filter provides.
The study is interventional in nature, with a single-group model and no masking. Its primary purpose is basic science, focusing on understanding the fundamental effects of filters on glare discomfort.
Key dates for the study include a start date of November 20, 2024, which is also the date of the last update submission. The study is currently not yet recruiting, indicating that participant enrollment is forthcoming.
The market implications of this study could be significant for Essilorluxottica’s stock performance, as positive results may enhance the company’s product offerings and competitive edge in the eyewear industry. Investors should watch for updates, as successful outcomes could influence market dynamics and investor sentiment.
The study is ongoing, with further details available on the ClinicalTrials portal.